ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc.

AcadeMedia AB ( ($SE:ACAD) ) just unveiled an update. AcadeMedia AB reported a 6.7% increase in net sales for the first quarter of 2025/26, driven ...

AcadeMedia AB Reports Strong Q1 Growth and Proposes Share Redemption

ACADIA Pharmaceuticals Inc. (($ACAD)) announced an update on their ongoing clinical study. Study Overview: ACADIA Pharmaceuticals Inc. is conductin...

ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204

Bank of America Securities analyst Tazeen Ahmad reiterated a Hold rating on ACADIA Pharmaceuticals today and set a price target of $27.00. The comp...

ACADIA Pharmaceuticals (ACAD) Receives a Hold from Bank of America Securities

An update from AcadeMedia AB ( ($SE:ACAD) ) is now available. AcadeMedia’s Board has proposed a voluntary share redemption program, aiming to optim...

AcadeMedia Proposes Voluntary Share Redemption Program

AcadeMedia AB ( ($SE:ACAD) ) has provided an announcement. AcadeMedia has announced a conference call and webcast for the presentation of its quart...

Market Cap	$3.55B	P/E Ratio	35.84
52W High	$26.65	52W Low	$13.40
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	48.9%	52W Position	80.1%
Overall Score	64	Value Score	75
Quality Score	57	Technical Score	60

EPS Current Est	$0.67	EPS Next Est	$0.71
EPS Growth Est	+6.0%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACAD	$24.01	-0.04%	1.20M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ACAD	$24.01	-0.0%	1.20M
3
4
5
6

ACAD

ACAD

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get ACADIA Pharmaceuticals Inc. Data in Excel

Get ACADIA Pharmaceuticals Inc. Data in Excel